KIM-1 Biomarker Analysis in IMmotion010: Adjuvant Atezolizumab for RCC at High Recurrence Risk

Laurence Albiges, MD, PhD, of Gustave Roussy Institute, breaks down a biomarker analysis of circulating kidney injury molecule-1 in the IMmotion010 trial.

Patients in this phase 3 trial had renal cell carcinoma, were at increased risk of recurrence after resection, and were randomized to adjuvant atezolizumab or placebo.

View her continued comments on KEYNOTE-B61: Extended Follow-Up Analysis.